NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-253-2020-0-US-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF US National Stage 18/033,656 Pending
NIAID E-001-2017-1-EP-01 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION EP DIV 23169546.1 Pending
NIAID E-064-2016-1-IN-02 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE IN DIV 202318029450 Pending
NIAID E-064-2016-1-IN-01 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE IN DIV 202318029501 Pending
NCI E-189-2020-1-CN-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION CN National Stage 202180072524.X Pending
NIDCR E-196-2021-0-PC-01 LENS ARRAY BASED IMAGING SYSTEM WITH IMPROVED FIELD OF VIEW PCT PCT PCT/US2023/019360 Expired
NIDCR E-130-2023-0-US-01 Treatment of Postsurgical Hypoparathyroidism by UsingTriphenyl Calcilytic Compounds US 63/497,693 Expired
NCI E-173-2020-0-CN-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 CN National Stage 202180071809.1 Pending
NCI E-143-2023-0-US-01 Repurposing Shingrix and Gardasil Immunity in Combination with a Tumor Associated Antigen US 63/497,348 Expired
NCI E-112-2022-0-PC-01 GENETICALLY ENGINEERED CELLS, THEIR USES, AND METHODS OF MAKING SAME PCT PCT PCT/US2023/066025 Pending
NCI E-211-2020-0-EP-01 PLK1 POLO DOMAIN INHIBITORS AND METHOD OF TREATING CANCER EP National Stage 21795110.2 Pending
NIDA E-199-2015-0-US-03 Method and Apparatus for the Capture of Intra-cellular Activity US CON 18/135,738 Pending
NCI E-211-2020-0-AU-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER AU National Stage 2021350736 Pending
NCI E-189-2020-1-GB-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION GB National Stage 2305617.9 Pending
NIDCR E-107-2022-1-NZ-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) NZ National Stage 799089 Pending
NHGRI E-147-2020-0-US-03 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXOCOBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS US National Stage 18/032,132 Pending
NIDCD E-043-2016-0-US-02 MICRORNAS AND METHODS OF THEIR USE US DIV 18/301,040 Pending
NIBIB E-007-2021-0-US-02 ANTIBODY SPECIFIC FOR SARS-COV-2 RECEPTOR BINDING DOMAIN AND THERAPEUTIC METHODS US National Stage 18/031,814 Pending
NCI E-107-2020-0-CN-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS CN National Stage 202180070402.7 Pending
NIAID E-004-2022-0-CA-01 STAR POLYMER DRUG CONJUGATES CA National Stage 3195623 Pending
NIBIB E-117-2023-0-US-01 FLUORINATED COUPLING PARTNER COMPOUNDS FOR RADIOLABELING BIOMOLECULES AND METHODS OF MAKING AND USING THE SAME US 63/459,079 Expired
NIAID E-178-2019-1-US-01 STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS US National Stage 18/031,602 Pending
NIEHS E-241-2020-0-US-02 Massively Paralleled Multi-patient Assay For Pathogenic Infection Diagnosis And Host Physiology Surveillance Using Nucleic Acid Sequencing US National Stage 18/031,165 Pending
NIMH E-070-2023-0-US-01 SYSTEMS AND METHODS FOR MULTICHANNEL INDIVIDUALIZED STIMULATION THERAPY US 63/495,244 Expired
NCATS E-120-2023-0-US-01 Small molecule modulators for the voltage-gated sodium channel 1.7 (NaV1.7) and their therapeutic applications US 63/495,159 Expired
NHLBI E-036-2022-0-PC-01 SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS PCT PCT PCT/US2023/017885 Expired
NCATS E-026-2016-0-US-02 Compounds for Improving mRNA Splicing US CON 18/297,569 Pending
NHLBI E-052-2022-0-PC-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PCT PCT PCT/US2023/017895 Expired
NHLBI E-111-2022-1-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM US 63/458,054 Expired
NIAID E-060-2022-0-PCT-02 BETA GLOBIN MIMETIC PEPTIDES AND THEIR USE PCT PCT PCT/US2023/065432 Expired
NIAID E-052-2017-4-JP-01 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection JP DIV 2023-061823 Pending
NCI E-175-2016-0-IL-01 ANTI-KRAS-G12D T CELL RECEPTORS IL DIV 301894 Pending
NINDS E-061-2023-0-US-01 SYSTEMS AND METHODS FOR PATTERNED MULTI-SLICE EXCITATION IN MAGNETIC RESONANCE IMAGING US 63/493,962 Expired
NCI E-173-2020-0-KR-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 KR National Stage 10-2023-7011380 Pending
NIAID E-131-2020-7-US-01 Anti-Coronavirus Antibodies And Methods Of Use US CON 18/194,105 Pending
NCI E-189-2020-1-JP-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION JP National Stage 2023-520143 Pending
NLM E-023-2023-0-PC-01 MODIFICATION-DEPENDENT ENRICHMENT OF DNA BY GENOME OF ORIGIN PCT PCT PCT/US2023/016926 Expired
NCATS E-253-2017-0-US-02 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME US DIV 18/128,603 Pending
NICHD E-010-2021-0-EP-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN EP National Stage 21824143.8 Pending
NCI E-167-2021-0-PC-01 Methods and Compositions for the Treatment for Inflammation and Fibrosis in Retinal
Neovascular Diseases 		PCT PCT PCT/US2023/065141 Expired
NCI E-173-2020-0-AU-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 AU National Stage 2021336399 Pending
NCI E-136-2023-0-US-01 ALLOSTERIC INHIBITORS OF THE POLO-LIKE KINASE 1 POLO BOX DOMAIN, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER US 63/455,608 Expired
NIDDK E-067-2022-1-PCT-02 A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS PCT PCT PCT/US2023/016769 Expired
NCI E-163-2020-0-EP-01 LZK-TARGETING DEGRADERS AND METHODS OF USE EP National Stage 21790644.5 Pending
NCI E-189-2020-1-CA-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION CA National Stage 3194229 Pending
NIAID E-073-2022-0-PC-01 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE PCT PCT PCT/US2023/065068 Expired
NCI E-189-2020-1-EP-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION EP National Stage 21810460.2 Pending
NCI E-167-2019-0-EP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY EP National Stage 21787116.9 Pending
NCI E-173-2020-0-EP-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 EP National Stage 21778318.2 Pending
NCI E-173-2020-0-IN-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 IN National Stage 202347022460 Pending